Key Financial Inc’s Xilio Therapeutics XLO Stock Holding History

Key Financial Inc’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$534	Hold	59	–	–	﹤0.01%	1224
2026 Q2	$565	Hold	59	–	–	﹤0.01%	1257
2026 Q1	$496	Hold	59	–	–	﹤0.01%	1306
2025 Q4	$531	Hold	59	–	–	﹤0.01%	1324
2025 Q3	$691	Hold	59	–	–	﹤0.01%	1309
2025 Q2	$564	Hold	59	–	–	﹤0.01%	1315
2025 Q1	$601	Hold	59	–	–	﹤0.01%	1269
2024 Q4	$793	Hold	59	–	–	﹤0.01%	1253
2024 Q3	$654	Hold	59	–	–	﹤0.01%	1234
2024 Q2	$786	Hold	59	–	–	﹤0.01%	1207
2024 Q1	$896	Hold	59	–	–	﹤0.01%	1195
2023 Q4	$456	Hold	59	–	–	﹤0.01%	1240
2023 Q3	$1.75K	Hold	59	–	–	﹤0.01%	1127
2023 Q2	$2.18K	Hold	59	–	–	﹤0.01%	1153
2023 Q1	$2.63K	Buy	+59	New	+$2.59K	﹤0.01%	918

Other funds holding XLO

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Key Financial Inc's XLO Position: Q3 2026 in Review

Key Financial Inc held its Xilio Therapeutics (XLO) position steady in Q3 2026 at 59 shares worth $534. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

Key Financial Inc first reported a position in XLO in Q1 2023 and has held it in 15 quarters since. The position peaked at $2.63K in Q1 2023. 4 funds tracked by Wall St. Rank hold XLO as of Q3 2026.

Key Financial Inc held 59 shares of Xilio Therapeutics worth $534 as of Q3 2026.
Key Financial Inc left its Xilio Therapeutics share count unchanged in Q3 2026.
Xilio Therapeutics made up ﹤0.01% of Key Financial Inc's portfolio in Q3 2026, its #1224 holding.
Key Financial Inc first reported a position in Xilio Therapeutics in Q1 2023 and has held it in 15 quarters since.
Key Financial Inc's Xilio Therapeutics position peaked at $2.63K in Q1 2023.
4 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.

Based on Key Financial Inc's 13F filing for Q3 2026, filed 2 Nov 2026.